3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
NET
29
Gastrointestinal
29
Endocrine
29
CNS
4
Sarcoma
3
Thoracic
2
Lymphoid
2
Gynecologic
2
Other solid neoplasm
1
Head & Neck
1
Dermatologic
1
Breast
1
Conditions
Lymphoma
549
Precursor Cell Lymphoblastic Leukemia-Lymphoma
511
Lymphoma, Non-Hodgkin
437
Lymphoma, Follicular
405
Lymphoma, Large B-Cell, Diffuse
392
Leukemia, Lymphocytic, Chronic, B-Cell
392
Lymphoma, B-Cell
248
Lymphoma, Mantle-Cell
224
Hodgkin Disease
209
Recurrence
205
Leukemia, Myeloid, Acute
199
Leukemia
196
Multiple Myeloma
185
Burkitt Lymphoma
185
Lymphoma, B-Cell, Marginal Zone
170
Neoplasms
153
Myelodysplastic Syndromes
134
Hematologic Neoplasms
115
Waldenstrom Macroglobulinemia
103
Lymphoma, T-Cell, Peripheral
86
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
83
Lymphoma, T-Cell
82
Lymphoma, T-Cell, Cutaneous
67
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
63
Mycosis Fungoides
57
Leukemia, Biphenotypic, Acute
55
Breast Neoplasms
55
Leukemia, B-Cell
52
Myeloproliferative Disorders
50
Lymphoproliferative Disorders
47
Interventions
pasireotide
1
amino-acid, glucose, and electrolyte solution
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Lymphoid
×
1 year
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled
NCT06784752
2026-04-30
NETTER-3
Novartis
Phase 3
Recruiting
240 enrolled